Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study.

Hemodialysis patients are frequently affected by peptic disease, and in many cases they have high serum levels of gastrine. The aim of this study was to evaluate the effects of omeprazole, an inhibitor of gastric parietal cells hydrogen pump, on peptic disease and gastric secretion of 16 selected dialysis patients. H2-receptors blocking drugs or gastric acidity buffers were withdrawn for 2 weeks, then omeprazole was administered for 4 weeks at a daily dosage of 20 mg. Before and after the omeprazole therapy, registration of subjective peptic symptoms, baseline serum gastrin dosage and endoscopy of upper digestive tract were performed